Yazar "Karabulut-Uzuncakmak, Sevgi" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Effect of boric acid, calcium fructoborate and potassium boron citrate on bone health and systemic inflammatory markers in rats
    (Turkish Energy Nuclear and Mining Research Institute, 2023) Karabulut-Uzuncakmak, Sevgi
    The aim of this study was to examine the effects of boron compounds on bone health. For this purpose, twenty-four Wistar rats were used. The animals were divided into four groups the control group and the groups to which boron varieties were administered. Three groups were given 3 mg/kg boric acid (BA), calcium fructoborate (CaFB), and potassium boron citrate (KBCi) orally by gavage for three weeks. TNF-?, IL1-?, total antioxidant level (TAS), total oxidant level (TOS), osteopontin, and osteocalcin levels were measured in serum and bone tissues of animals by ELISA method. There was no significant difference between the groups for TNF-?, IL-1? and TOS levels, and serum osteopontin and osteocalcin levels in the serum samples and bone tissues obtained from the control group and rat groups to which boron compounds were administered (p>0.05). When the serum TAS level was compared to the control group and BA, CaFB, and KBCi applied groups, it showed a significant increase in the groups to which boron compounds were administered (p<0.0001). Bone TAS level was also found to be relatively high in the groups treated with boron varieties (p=0.0005). Bone tissue osteopontin and osteocalcin values increased with the application of BA, CaFB, and KBCi (p<0.0001). The effects of BA, CaFB, and KBCi on bone health have been compared in this study. This study is promising as a preliminary study for more comprehensive studies to be carried out in order to use boron compounds such as BA, CaFB, and KBCi more widely in the future in order to improve bone health, and prevent bone diseases or cope with increased stress due to various factors. © 2023, Turkish Energy Nuclear and Mining Research Institute. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Evaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patients
    (Medical University of Bialystok, 2023) Karabulut-Uzuncakmak, Sevgi; Aksakal, Alperen; Kerget, Ferhan; Aydin, Pelin; Halıcı, Zekai
    Purpose: The aim of this study is to investigate insulin-like growth factor binding protein 5 (IGFBP5) expression in coronavirus disease 2019 (COVID-19) patients and its relationships with COVID-19 laboratory findings and plasma osteopontin (OPN) levels. Materials and methods: We enrolled 60 patients with COVID-19 and 30 healthy individuals in this study. mRNA expression of IGFBP5 was measured by RT-PCR. Plasma OPN levels were measured via the ELISA method. Results: Plasma OPN levels were higher and IGFBP5 expression levels were lower in COVID-19 patients than in the healthy individuals (p ?= ?0.0057 and p ?= ?0.0142, respectively). Critically ill patients had higher OPN and lower IGFBP5 than non-critically ill patients. Patients with affected lungs demonstrated increased OPN and decreased IGFBP5 (p ?= ?0.00032 and p ?= ?0.044, respectively). Receiver operating characteristic (ROC) analysis indicated that IGFBP5 expression and OPN levels can be used discriminate non-critically from critically ill patients (p ?= ?0.049; p ?= ?0.0016, respectively). Conclusion: This study demonstrated that patients with a poor prognosis had increased OPN and decreased IGFBP5. High values of OPN and low values of IGFBP5 may be considered as signs of disease severity. Tissue-specific IGFBP5 expression may contribute to understanding the role of IGFBP5 in the lungs in COVID-19 cases. © 2022 Medical University of Bialystok
  • Küçük Resim Yok
    Öğe
    The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-?1/HMGB1 signaling pathway
    (Elsevier Urban & Partner Sp Z O O, 2023) Aydin, Pelin; Aksakalli-Magden, Zeynep B.; Civelek, Maide S.; Karabulut-Uzuncakmak, Sevgi; Mokhtare, Behzad; Ozkaraca, Mustafa; Alper, Fatih
    Purpose: The possible effects of ramelteon, a melatonin receptor agonist on bleomycin-induced lung fibrosis were analyzed via transforming growth factor beta 1 (TGF-beta 1), the high mobility group box 1 (HMGB1) and Nod-like receptor pyrin domain-containing 3 (NLRP3) which are related to the fibrosis process. Materials and methods: Bleomycin (0.1 mL of 5 mg/kg) was administered by intratracheal instillation to induce pulmonary fibrosis (PF). Starting 24 h after bleomycin administration, a single dose of ramelteon was administered by oral gavage to the healthy groups, i.e. PF + RM2 (pulmonary fibrosis model with bleomycin + ramelteon at 2 mg/kg) and PF + RM4 (pulmonary fibrosis model with bleomycin + ramelteon at 4 mg/kg) at 2 and 4 mg/kg doses, respectively. Real-time polymerase chain reaction (real-time PCR) analyses, histopathological, and immunohistochemical staining were performed on lung tissues. Lung tomography images of the rats were also examined. Results: The levels of TGF-beta 1, HMGB1, NLRP3, and interleukin 1 beta (IL-1 beta) mRNA expressions increased as a result of PF and subsequently decreased with both ramelteon doses (p < 0.0001). Both doses of ramelteon partially ameliorated the reduction in the peribronchovascular thickening, ground-glass appearances, and reticulations, and the loss of lung volume. Conclusions: The severity of fibrosis decreased with ramelteon application. These effects of ramelteon may be associated with NLRP3 inflammation cascade.